Literature DB >> 22806612

Comparative effectiveness research: does one size fit all?

Lauren M Kunz1, Robert W Yeh, Sharon-Lise T Normand.   

Abstract

In this commentary, we argue that although randomization has many benefits, not all questions we seek to answer fit into a randomized setting. Our argument utilizes the clinical setting of carotid atherosclerosis management where specific clinical questions are answered by using a variety of comparative effectiveness designs. Observational studies should not be ruled out when designing studies to address questions of comparative effectiveness.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22806612      PMCID: PMC5048192          DOI: 10.1002/sim.5482

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  11 in total

1.  Do postmarketing surveillance studies represent real-world populations? A comparison of patient characteristics and outcomes after carotid artery stenting.

Authors:  Robert W Yeh; Kevin Kennedy; John A Spertus; Sahil A Parikh; Rahul Sakhuja; H Vernon Anderson; Christopher J White; Kenneth Rosenfield
Journal:  Circulation       Date:  2011-03-21       Impact factor: 29.690

2.  Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change.

Authors:  Bryan R Luce; Judith M Kramer; Steven N Goodman; Jason T Connor; Sean Tunis; Danielle Whicher; J Sanford Schwartz
Journal:  Ann Intern Med       Date:  2009-06-30       Impact factor: 25.391

3.  Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial.

Authors:  Hans-Henning Eckstein; Peter Ringleb; Jens-Rainer Allenberg; Jürgen Berger; Gustav Fraedrich; Werner Hacke; Michael Hennerici; Robert Stingele; Jens Fiehler; Hermann Zeumer; Olav Jansen
Journal:  Lancet Neurol       Date:  2008-09-05       Impact factor: 44.182

4.  What is the current status of invasive treatment of extracranial carotid artery disease?

Authors:  A Ross Naylor
Journal:  Stroke       Date:  2011-06-09       Impact factor: 7.914

5.  Using Multiple Control Groups and Matching to Address Unobserved Biases in Comparative Effectiveness Research: An Observational Study of the Effectiveness of Mental Health Parity.

Authors:  Frank B Yoon; Haiden A Huskamp; Alisa B Busch; Sharon-Lise T Normand
Journal:  Stat Biosci       Date:  2011-06-21

6.  Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial.

Authors:  Jörg Ederle; Joanna Dobson; Roland L Featherstone; Leo H Bonati; H Bart van der Worp; Gert J de Borst; T Hauw Lo; Peter Gaines; Paul J Dorman; Sumaira Macdonald; Philippe A Lyrer; Johanna M Hendriks; Charles McCollum; Paul J Nederkoorn; Martin M Brown
Journal:  Lancet       Date:  2010-02-25       Impact factor: 79.321

7.  Better outcomes for patients treated at hospitals that participate in clinical trials.

Authors:  Sumit R Majumdar; Matthew T Roe; Eric D Peterson; Anita Y Chen; W Brian Gibler; Paul W Armstrong
Journal:  Arch Intern Med       Date:  2008-03-24

8.  Long-term results of carotid stenting versus endarterectomy in high-risk patients.

Authors:  Hitinder S Gurm; Jay S Yadav; Pierre Fayad; Barry T Katzen; Gregory J Mishkel; Tanvir K Bajwa; Gary Ansel; Neil E Strickman; Hong Wang; Sidney A Cohen; Joseph M Massaro; Donald E Cutlip
Journal:  N Engl J Med       Date:  2008-04-10       Impact factor: 91.245

9.  Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.

Authors: 
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

10.  Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial.

Authors:  Jean-Louis Mas; Ludovic Trinquart; Didier Leys; Jean-François Albucher; Hervé Rousseau; Alain Viguier; Jean-Pierre Bossavy; Béatrice Denis; Philippe Piquet; Pierre Garnier; Fausto Viader; Emmanuel Touzé; Pierre Julia; Maurice Giroud; Denis Krause; Hassan Hosseini; Jean-Pierre Becquemin; Grégoire Hinzelin; Emmanuel Houdart; Hilde Hénon; Jean-Philippe Neau; Serge Bracard; Yannick Onnient; Raymond Padovani; Gilles Chatellier
Journal:  Lancet Neurol       Date:  2008-09-05       Impact factor: 44.182

View more
  3 in total

1.  Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry.

Authors:  Robert W Yeh; Matthew J Czarny; Sharon-Lise T Normand; Dean J Kereiakes; David R Holmes; Ralph G Brindis; W Douglas Weaver; John S Rumsfeld; Matthew T Roe; Sunghee Kim; Priscilla Driscoll-Shempp; Laura Mauri
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-11-16

2.  Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism.

Authors:  Pamela L Lutsey; Neil A Zakai; Richard F MacLehose; Faye L Norby; Rob F Walker; Nicholas S Roetker; Terrence J Adam; Alvaro Alonso
Journal:  Br J Haematol       Date:  2019-03-28       Impact factor: 6.998

3.  All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.

Authors:  Nicholas S Roetker; Pamela L Lutsey; Neil A Zakai; Alvaro Alonso; Terrence J Adam; Richard F MacLehose
Journal:  Thromb Haemost       Date:  2018-08-13       Impact factor: 5.249

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.